Table 1.
Demographic and clinical characteristics of included PPMI study participants
| Baseline N=362 |
Month 12 N=318 |
Month 24 N=312 |
Month 36 N=317 |
Month 48 N=240 |
Month 60 N=107 |
|
|---|---|---|---|---|---|---|
| Age (y) | 61.3 (9.8) | |||||
| Gender (% female) | 33.7% | |||||
| % Treated with dopaminergic medications | 0% | 57.9% | 83.3% | 90.9% | 95.4% | 90.7% |
| MDS-UPDRS Total Score | 27.56 (11.48) | 33.09 (14.16) | 36.71 (15.55) | 39.61 (16.74) | 44.92 (19.76) | 47.59 (21.27) |
| MDS-UPDRS Part I Score | 1.19 (1.55) | 1.49 (1.81) | 1.68 (2.03) | 1.88 (2.18) | 2.29 (2.58) | 2.54 (2.86) |
| MDS-UPDRS Part II Score | 5.67 (4.13) | 7.27 (4.93) | 7.84 (5.25) | 8.57 (5.42) | 10.04 (6.64) | 10.73 (6.92) |
| MDS-UPDRS Part III Score | 20.72 (8.85) | 24.11 (10.27) | 26.70 (11.26) | 28.37 (12.06) | 31.38 (12.84) | 32.54 (14.65) |
| MDS-UPDRS Part IV Score | N/A | 0.36 (1.20) | 0.60 (1.61) | 0.87 (1.85) | 1.34 (2.30) | 1.96 (2.51) |
Values shown as mean (SD) except where indicated
Abbreviations: MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale